| Literature DB >> 27231040 |
Wei Qian1, Kuanfeng Xu1, Wenting Jia1, Ling Lan2, Xuqin Zheng1, Xueyang Yang1, Dai Cui3.
Abstract
Thyroid stimulating hormone receptor (TSHR) is thought to be a significant candidate for genetic susceptibility to Graves' disease (GD). However, the association between TSHR gene polymorphism and the risk of GD remains controversial. In this study, we investigated the relationship between the two conditions by meta-analysis. We searched all relevant case-control studies in PubMed, Web of Science, CNKI and Wanfang for literature available until May 2015, and chose studies on two single nucleotide polymorphisms (SNPs): rs179247 and rs12101255, within TSHR intron-1. Bias of heterogeneity test among studies was determined by the fixed or random effect pooled measure, and publication bias was examined by modified Begg's and Egger's test. Eight eligible studies with 15 outcomes were involved in this meta-analysis, including 6,976 GD cases and 7,089 controls from China, Japan, Poland, UK and Brazil. Pooled odds ratios (ORs) for allelic comparisons showed that both TSHR rs179247A/G and rs12101255T/C polymorphism had significant association with GD (OR=1.422, 95%CI=1.353-1.495, P<0.001, Pheterogeneity=0.448; OR=1.502, 95%CI: 1.410-1.600, P<0.001, Pheterogeneity=0.642), and the associations were the same under dominant, recessive and co-dominant models. In subgroup analyses, the conclusions are also consistent with all those in Asian, European and South America subgroups (P<0.001). Our meta-analysis revealed a significant association between TSHR rs179247A/G and rs12101255T/C polymorphism with GD in five different populations from Asia, Europe and South America. Further studies are needed in other ethnic backgrounds to independently confirm our findings.Entities:
Keywords: Graves' disease; meta-analysis; polymorphism; thyroid stimulating hormone receptor
Year: 2015 PMID: 27231040 PMCID: PMC5138578 DOI: 10.7555/JBR.30.20140144
Source DB: PubMed Journal: J Biomed Res ISSN: 1674-8301
Fig. 1Selection of articles for inclusion and excluding in the meta-analysis.
Characteristics of the rs179247A/G polymorphism allelic and genotype distribution for GD risk in studies included in the meta-analysis.
| Authors[ref.] | Year | Ethnicity | Methods | HWE | Total/Genotypes(AA/AG/GG) | A allele frequency(%) | OR(95% CI) | ||
| Cases | Controls | Cases | Controls | ||||||
| Oliver J. Brand et al | 2009 | European | Taq man | 0.454 | 768 (279 /359 /100) | 768 (182/ 322 / 160) | 46.0 | 38.0 | 1.54 (1.32–1.78) |
| Rafał Płoski et al | 2010 | European Set 1 | Taq man | 0.443 | 558 (139 / 270 /149) | 520 (81 / 259 / 180) | 49.1 | 40.5 | 1.42 (1.20–1.68) |
| Rafał Płoski et al | 2010 | European Set 2 | Taq man | 0.857 | 196 (58 / 84 / 54) | 198 (34 / 98 / 67) | 51.0 | 41.7 | 1.46 (1.10–1.93) |
| Rafał Płoski et al | 2010 | European Set 3 | Taq man | 0.393 | 2504 (879 /1110 / 351) | 2784 (737 /1243 / 561) | 61.3 | 53.5 | 1.38 (1.27–1.49) |
| Shaoying Yang et al | 2011 | Asian | Taq man | 0.471 | 1066 (564/427/75) | 1107 (486/503/118) | 72.9 | 66.6 | 1.35 (1.19-1.54) |
| Lin Liu et al | 2012 | Asian | MALDI-TOFMS | 0.504 | 404 (230/140/24) | 242 (120/88/20) | 76.14 | 71.93 | 1.25 (0.96-1.62) |
| Ran Wang et al | 2012 | Asian | Taq man | 0.859 | 618 (353/220/45) | 646 (260/298/88) | 74.92 | 63.31 | 1.73 (1.46-2.05) |
| Haili Wang et al | 2013 | Asian | Taq man | 0.713 | 471 (258/174/38) | 472 ( 216/204/52) | 73.4 | 67.4 | 1.34 (1.10-1.63) |
| N. Inoue1 et al | 2013 | Asian | PCR-RFLP | 0.066 | 112 (57/44/11) | 56 (18/33/5) | 70.5 | 61.6 | 1.49 (0.93-1.50) |
| N. E. Bufalo et al | 2015 | South America | Taq man | 0.213 | 279 (117/138/24) | 296 (92/154/50) | 66.7 | 57.1 | 2.82 (1.56–4.99) |
Characteristics of the rs12101255T/C polymorphism allelic and genotype distribution for GD risk in studies included in the meta-analysis.
| Authors[ref.] | Year | Ethnicity | Methods | HWE | Total/Genotypes(TT /TC/ CC) | T allele frequency(%) | OR(95% CI) | ||
|---|---|---|---|---|---|---|---|---|---|
| Cases | Controls | Cases | Controls | ||||||
| Oliver J. Brand et al | 2009 | European | Taq man | 0.964 | 768 (150/345 /197) | 768 (89/ 295 / 268) | 35.0 | 28.0 | 1.55( 1.33–1.81) |
| Rafał Płoski et al | 2010(1) | European Set 1 | Taq man | 0.473 | 558 (75 /245 /238) | 520 (35 / 212 / 273) | 35.4 | 27.1 | 1.47( 1.23–1.77) |
| Rafał Płoski et al | 2010(2) | European Set 2 | Taq man | 0.261 | 196 (32 /94 /70) | 198 (17 /71 /110) | 40.3 | 26.5 | 1.87( 1.39–2.53) |
| Rafał Płoski et al | 2010(3) | European Set 3 | Taq man | 0.412 | 2504 (482/1136 / 687) | 2784 (338/1148 / 1046) | 45.6 | 36.0 | 1.49( 1.37–1.61) |
| Lin Liu et al | 2012 | Asian | MALDI-TOFMS | 0.550 | 404 (187/179/38) | 242 (86/119/35) | 68.44 | 60.63 | 1.41(1.11-1.78) |
Pooled measures for the association between the rs179247A/G and rs12101255T/C polymorphisms and susceptibility to GD risk.
| SNPs | Inherited model | Ethnicity | Studies(cases/controls) | Model | Effects | |||
| I2(%) | OR(95%CI) | |||||||
| rs179247 | Per allele (A vs. G) | overall | 10(6976/7089) | 0.448 | 0 | FEM | 1.422(1.353-1.495) | <0.0001 |
| European | 4(4026/4270) | 0.662 | 0 | FEM | 1.415(1.327-1.508) | <0.0001 | ||
| Asian | 5(2671/2523) | 0.133 | 43.4 | FEM | 1.426(1.310-1.553) | <0.0001 | ||
| South America | 1(279/296) | 0 | 0 | FEM | 1.503(1.183-1.910) | 0.001 | ||
| Dominant (AA +AG vs. GG) | overall | 10(6976/7089) | 0.537 | 0 | FEM | 1.632(1.484-1.796) | <0.0001 | |
| European | 4(4026/4270) | 0.263 | 24.7 | FEM | 1.618(1.447-1.810) | <0.0001 | ||
| Asian | 5(2671/2523) | 0.589 | 0 | FEM | 1.609(1.327-1.952) | <0.0001 | ||
| South America | 1(279/296) | 0 | 0 | FEM | 2.160(1.287-3.623) | 0.004 | ||
| Recessive (AA vs. AG+GG) | overall | 10(6976/7089) | 0.264 | 19.4 | FEM | 1.552(1.445-1.667) | <0.0001 | |
| European | 4(4026/4270) | 0.395 | 0 | FEM | 1.550(1.406-1.710) | <0.0001 | ||
| Asian | 5(2671/2523) | 0.086 | 51.0 | REM | 1.561(1.311-1.858) | <0.0001 | ||
| South America | 1(279/296) | 0 | 0 | FEM | 1.601(1.137-2.255) | 0.007 | ||
| Co-dominant (AA vs. GG) | overall | 10(6976/7089) | 0.653 | 0 | FEM | 2.022(1.816-2.252) | <0.0001 | |
| European | 4(4026/4270) | 0.572 | 0 | FEM | 2.028(1.779-2.312) | <0.0001 | ||
| Asian | 5(2671/2523) | 0.443 | 0 | FEM | 1.937(1.585-2.368) | <0.0001 | ||
| South America | 1(279/296) | 0 | 0 | FEM | 2.649(1.516-4.630) | 0.001 | ||
| rs12101255 | Per allele (T vs. C) | overall | 5(4430/4512) | 0.642 | 0 | FEM | 1.502(1.410-1.600) | <0.0001 |
| Dominant (TT + TC vs. CC) | overall | 5(4430/4512) | 0.528 | 0 | FEM | 1.672(1.525-1.834) | <0.0001 | |
| Recessive (TT vs. TC + CC) | overall | 5(4430/4512) | 0.766 | 0 | FEM | 1.741(1.548-1.957) | <0.0001 | |
| Co-dominant (TT vs. CC) | overall | 5(4430/4512) | 0.882 | 0 | FEM | 2.236(1.956-2.556) | <0.0001 | |
Fig. 2Stratified analysis pooled odds ratios for the association between the rs179247A/G polymorphism and susceptibility to GD risk.
Fig. 3Stratified analysis pooled odds ratios for the association between the rs12101255T/C polymorphism and susceptibility to GD risk.
Fig. 4Sensitivity analyses for rs179247A/G polymorphisms in GD.
Fig. 5Sensitivity analyses for rs12101255T/C polymorphisms in GD.
Egger's publication bias test for rs179247A/G and rs12101255T/C polymorphisms in GD.
| Coef. (a) | Std. Err. (b) | 95% CI of intercept | ||||
| rs179247A/G | –.2301901 | 1.744951 | -0.13 | 0.898 | -4.254053 | 3.793673 |
| rs12101255T/C | –3.959451 | 8.958683 | -0.44 | 0.688 | -32.46998 | 24.55108 |
a Coefficient; b Standard error.